- Details
- Sam Chang interviews Joseph Jacob about a registry trial examining the effectiveness of Jelmyto (UGN-101) in treating ureteral tumors. Dr. Jacob presents data from a retrospective study involving 23 patients across 15 high-volume centers in the US. The study explores the use of Jelmyto beyond its initial indication in renal pelvis tumors, focusing on its application in ureteral tumors. Dr. Jacob r...
|
- Details
- Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy. Dr. Crispen discusses the findings, which show that patients with a history of upper tract disease experience bladder tumor recurrences sooner than those with primary bladder tumors, despite similar overall recurrence rates. The study reveals a higher ris...
|
- Details
- Sam Chang interviews Surena Matin about a phase 1b trial evaluating FGFR3 inhibition in localized upper tract urothelial carcinoma (UTUC). Dr. Matin discusses the study's rationale, design, and results, highlighting the high prevalence of FGFR3 mutations in UTUC and the need for better management strategies. The trial demonstrates that FGFR inhibition with infigratinib is well-tolerated and rapidl...
|
- Details
- Zach Klaassen welcomes Vitaly Margulis to discuss the ENLIGHTED trial, a phase three study addressing low-grade upper tract urothelial carcinoma. Dr. Margulis explains the necessity of the trial by highlighting the common over-treatment of this cancer type due to the limited and challenging endoscopic management options available. The trial focuses on Vascular Targeted Photodynamic therapy (VTP),...
|
- Details
- Hideki Furuya presents promising findings on a new urine test, Oncuria-Detect, for diagnosing upper tract urothelial carcinoma (UTUC). Given that UTUC is a rare cancer often difficult to detect early, this non-invasive test is a significant advancement. Oncuria-Detect, originally developed for bladder cancer, measures ten biomarkers associated with urothelial cancers. Dr. Furuya's study, involving...
|
- Details
- Sam Chang hosts Alison Birtle to discuss the final results of the POUT trial for upper tract urothelial carcinoma. Dr. Birtle highlights the trial's significance, conducted across 75 UK centers and supported by Cancer Research UK, emphasizing the involvement of patients and their families. The study, addressing an unmet need in UTUC, compared adjuvant chemotherapy with surveillance, showing signif...
|
- Details
- Sam Chang converses with Helen Hougen about her presentation on predictive biomarkers for upper tract urothelial carcinoma (UTUC) at the SUO, emphasizing their critical role in risk stratification. They delve into the limitations of current diagnostic tools like ureteroscopic biopsies, which often provide imperfect information and pose significant patient burdens. Highlighting the promise of minim...
|
- Details
- Sam Chang engages with Jennifer Linehan to discuss topical chemotherapy for upper tract urothelial carcinoma, particularly utilizing UGN-101 (Jelmyto). Dr. Linehan shares her invaluable insights and experiences, primarily from the OLYMPUS trial, highlighting the evolution in administration methods for UGN-101, transitioning from retrograde to the more convenient antegrade approach via a nephrostom...
|
- Details
- Sam Chang engages in a detailed discussion with Hristos Kaimakliotis, who presents findings from a multi-institutional review he authored, focusing on real-world practices with Jelmyto, a treatment for upper tract urothelial cancer. The study explores the efficacy of mitomycin reverse thermal gel, UGN-101, which has shown promise in ablating low-grade upper tract urothelial cancer. The OLYMPUS tri...
|
- Details
- In a case presentation, Zach Klaassen and Kyle Rose discuss the complexities of treating low-grade upper tract urothelial carcinoma. Dr. Rose presents a case of a 69-year-old male patient with the condition, emphasizing the importance of thorough workup and staging. The discussion covers the challenges of accurate biopsy sampling and the potential for under-staging or over-staging patients. Dr. Ro...
|
